Jazz Pharmaceuticals PLC (JAZZ) Shares Sold by Schroder Investment Management Group

Share on StockTwits

Schroder Investment Management Group cut its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 34.7% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 144,553 shares of the specialty pharmaceutical company’s stock after selling 76,747 shares during the period. Schroder Investment Management Group owned about 0.24% of Jazz Pharmaceuticals worth $25,132,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. FMR LLC raised its position in Jazz Pharmaceuticals by 12.1% during the second quarter. FMR LLC now owns 6,634,958 shares of the specialty pharmaceutical company’s stock worth $1,143,203,000 after acquiring an additional 715,595 shares during the period. BlackRock Inc. grew its holdings in shares of Jazz Pharmaceuticals by 64.0% during the second quarter. BlackRock Inc. now owns 4,372,080 shares of the specialty pharmaceutical company’s stock worth $753,311,000 after buying an additional 1,706,417 shares in the last quarter. Partner Fund Management L.P. grew its holdings in shares of Jazz Pharmaceuticals by 9.1% during the second quarter. Partner Fund Management L.P. now owns 1,238,906 shares of the specialty pharmaceutical company’s stock worth $213,464,000 after buying an additional 103,379 shares in the last quarter. Boston Partners grew its holdings in shares of Jazz Pharmaceuticals by 1.8% during the second quarter. Boston Partners now owns 1,089,656 shares of the specialty pharmaceutical company’s stock worth $187,748,000 after buying an additional 18,821 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of Jazz Pharmaceuticals by 10.5% during the second quarter. Wells Fargo & Company MN now owns 510,150 shares of the specialty pharmaceutical company’s stock worth $87,898,000 after buying an additional 48,455 shares in the last quarter. Institutional investors own 92.52% of the company’s stock.

Shares of JAZZ opened at $158.82 on Friday. The company has a quick ratio of 3.62, a current ratio of 3.76 and a debt-to-equity ratio of 0.54. Jazz Pharmaceuticals PLC has a 12-month low of $128.58 and a 12-month high of $184.00. The stock has a market capitalization of $10.16 billion, a P/E ratio of 16.66, a PEG ratio of 0.92 and a beta of 1.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.23 by $0.26. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%. The firm had revenue of $500.48 million during the quarter, compared to analyst estimates of $469.85 million. Equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 11.7 EPS for the current year.

In related news, EVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $175.70, for a total value of $35,140.00. Following the completion of the sale, the executive vice president now owns 25,572 shares of the company’s stock, valued at $4,493,000.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Rick E. Winningham sold 16,639 shares of the company’s stock in a transaction dated Friday, August 10th. The shares were sold at an average price of $176.18, for a total transaction of $2,931,459.02. Following the completion of the sale, the director now directly owns 15,594 shares of the company’s stock, valued at approximately $2,747,350.92. The disclosure for this sale can be found here. Insiders sold 34,778 shares of company stock valued at $6,011,022 in the last three months. 3.90% of the stock is currently owned by insiders.

JAZZ has been the subject of a number of research reports. Wells Fargo & Co reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a report on Sunday, July 8th. BidaskClub lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 18th. Morgan Stanley lowered shares of Jazz Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $183.00 target price for the company. in a report on Wednesday, July 11th. Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, July 16th. Finally, Leerink Swann upped their target price on shares of Jazz Pharmaceuticals from $200.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, August 17th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company’s stock. Jazz Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $192.11.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: What Is An Exchange-Traded Fund (ETF)?

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply